PE20071150A1 - Un proceso para preparar derivados de tetrahidroquinolina - Google Patents

Un proceso para preparar derivados de tetrahidroquinolina

Info

Publication number
PE20071150A1
PE20071150A1 PE2007000358A PE2007000358A PE20071150A1 PE 20071150 A1 PE20071150 A1 PE 20071150A1 PE 2007000358 A PE2007000358 A PE 2007000358A PE 2007000358 A PE2007000358 A PE 2007000358A PE 20071150 A1 PE20071150 A1 PE 20071150A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
ethyl
ona
quinolin
dihydro
Prior art date
Application number
PE2007000358A
Other languages
English (en)
Inventor
Masaki Okamoto
Akira Sakuragi
Yoshikazu Mori
Takeshi Hamada
Hitoshi Kubota
Yoshinori Nakamura
Takanori Higashijima
Norimitsu Hayashi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PE20071150A1 publication Critical patent/PE20071150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE UN COMPUESTO DE FORMULA (I-a) O (2R,4S)-2-ETIL-6-TRIFLUOROMETIL-1,2,3,4-TETRAHIDROQUINOLIN-4-ILAMINA, QUE COMPRENDE: A) HACER REACCIONAR ACIDO (R)-3-AMINOVALERICO O SU ESTER ALQUILICO CON UN COMPUESTO DE FORMULA (I-f) PARA FORMAR ACIDO (R)-3-(4-TRIFLUOROMETIL-FENILAMINO)-VALERICO, DONDE L ES UN GRUPO SALIENTE; B) HACER REACCIONAR ACIDO (R)-3-(4-TRIFLUOROMETIL-FENILAMINO)-VALERICO CON PENTOXIDO DE FOSFORO EN PRESENCIA DE ACIDO METANSULFONICO PARA FORMAR (R)-2-ETIL-6-TRIFLUOROMETIL-2,3-DIHIDRO-1H-QUINOLIN-4-ONA; C) CONVERTIR (R)-2-ETIL-6-TRIFLUOROMETIL-2,3-DIHIDRO-1H-QUINOLIN-4-ONA EN OXIMA DE (R)-2-ETIL-6-TRIFLUOROMETIL-2,3-DIHIDRO-1H-QUINOLIN-4-ONA O EN O-ALQUIALQUIL-OXIMA DE (R)-2-ETIL-6-TRIFLUOROMETIL-2,3-DIHIDRO-1H-QUINOLIN-4-ONA; Y D) REALIZAR UNA REDUCCION CATALITICA DE LA OXIMA U O-ALQUIALQUIL-OXIMA EN PRESENCIA DEL CATALIZADOR DE PALADIO-CARBONO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE COMPUESTOS DE FORMULA (I), (II), ENTRE OTROS. DICHO COMPUESTO OBTENIDO ES INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE ESTER DE COLESTERILO (CETP) SIENDO UTIL EN EL TRATAMIENTO DE HIPERLIPIDEMIA
PE2007000358A 2006-03-30 2007-03-29 Un proceso para preparar derivados de tetrahidroquinolina PE20071150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006092783 2006-03-30
JP2006322845 2006-11-30

Publications (1)

Publication Number Publication Date
PE20071150A1 true PE20071150A1 (es) 2007-12-03

Family

ID=38123770

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000358A PE20071150A1 (es) 2006-03-30 2007-03-29 Un proceso para preparar derivados de tetrahidroquinolina

Country Status (10)

Country Link
US (1) US8084611B2 (es)
EP (2) EP2007728B1 (es)
JP (1) JP5275971B2 (es)
AR (1) AR060174A1 (es)
AT (1) ATE533747T1 (es)
ES (1) ES2374315T3 (es)
PE (1) PE20071150A1 (es)
TW (1) TW200808731A (es)
UY (1) UY30244A1 (es)
WO (1) WO2007116922A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008324243B2 (en) * 2007-11-05 2012-03-08 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
EP2404901B1 (en) * 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
CN102020608B (zh) * 2010-09-17 2012-09-05 清华大学 喹啉化合物的制备方法
DK3180314T3 (da) * 2014-08-12 2022-08-29 Newamsterdam Pharma B V Fremgangsmåde til fremstilling af syntetiske mellemprodukter til fremstilling af tetrahydroquinolin-derivater
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
KR102455390B1 (ko) 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
EP3590927A1 (en) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
CA3114618C (en) 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN113614084A (zh) 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
WO2022185120A1 (en) 2021-03-05 2022-09-09 Newamsterdam Pharma B.V. Obicetrapib for treatment of dementias
WO2023006657A1 (en) 2021-07-26 2023-02-02 Newamsterdam Pharma B.V. Treatment of his hyporesponders
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
CN114516865B (zh) * 2022-03-09 2023-06-23 成都师范学院 一类D-π-A型有机共轭分子及其制备方法和应用
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82094C (fi) 1989-02-16 1997-09-09 Valmet Corp Anvaendning av en legering av ett metallpulver och en karbid eller nitrid innefattande belaeggningskomposition foer en i en pappersmaskin anvaendbar yankeecylinder
EP0386839B1 (en) 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PL286445A1 (en) 1989-08-11 1991-04-22 Ici Plc Method of obtaining novel quinoline derivatives
JPH03161360A (ja) 1989-11-21 1991-07-11 Tdk Corp サーマルヘッド
JPH03216566A (ja) 1990-01-22 1991-09-24 Mitsubishi Electric Corp Ｃｃｄリニアイメージセンサのテスト装置
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5929281A (en) 1996-04-19 1999-07-27 Tosoh Corporation Process for producing heterocyclic aromatic amine or arylamine
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
EP1167521A1 (en) 2000-06-30 2002-01-02 Aventis Animal Nutrition S.A. Coated enzyme-containing catalyst
WO2002008869A2 (en) 2000-07-25 2002-01-31 Digeo, Inc. Allowance account for interactive television system
JP2002053557A (ja) * 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白ａ−ｉ産生促進薬
ATE497385T1 (de) * 2000-08-18 2011-02-15 Ajinomoto Kk Neue phenylalanin-derivate
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
DK1383734T3 (da) 2001-04-30 2006-05-15 Pfizer Prod Inc Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater
EP1318139A3 (en) 2001-12-07 2003-07-30 Solvias AG Processes for the preparation of 3-aminocarboxylic acids and their esters
US6903233B2 (en) 2002-03-11 2005-06-07 Takasago International Corporation Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester
PT1533292E (pt) 2002-08-30 2007-05-31 Japan Tobacco Inc Compostos de dibenzilamina e sua utilização farmacêutica.
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
JP2004238322A (ja) 2003-02-05 2004-08-26 Sumika Fine Chemicals Co Ltd （ｒ）−３−アミノペンタンニトリルメタンスルホン酸塩の製造方法
WO2004072041A1 (en) 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
JP4644658B2 (ja) 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
EP1622872A1 (en) 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
US7145030B2 (en) 2003-04-24 2006-12-05 Ajinomoto Co., Inc. Production method for optically active N-aryl-β-amino acid compounds
JP2004339205A (ja) 2003-04-24 2004-12-02 Ajinomoto Co Inc 光学活性Ｎ−アリール−β−アミノ酸化合物の製造方法
DE602004025132D1 (de) 2003-09-18 2010-03-04 Takasago Perfumery Co Ltd Asymmetrische reduktive aminierung von ketosäurederivaten zur herstellung von aminosäurederivaten
CA2556826A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
DE602005014955D1 (de) 2004-03-26 2009-07-30 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法

Also Published As

Publication number Publication date
EP2007728B1 (en) 2011-11-16
WO2007116922A1 (en) 2007-10-18
AR060174A1 (es) 2008-05-28
UY30244A1 (es) 2007-11-30
TW200808731A (en) 2008-02-16
US8084611B2 (en) 2011-12-27
ATE533747T1 (de) 2011-12-15
JP5275971B2 (ja) 2013-08-28
ES2374315T3 (es) 2012-02-15
EP2154132A1 (en) 2010-02-17
JP2009532345A (ja) 2009-09-10
US20090292125A1 (en) 2009-11-26
EP2007728A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
PE20071150A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
PE20020340A1 (es) Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos
CU23999B1 (es) Solución no-acuosa tópica de diclofenaco y proceso para su preparación
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
PE20081563A1 (es) Proceso para la preparacion de inhibidores de nep
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
MXPA05006907A (es) Compuestos diazoicos cationicos, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo.
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
MA30652B1 (fr) Composes organiques
MA33840B1 (fr) Nouveau composé de spiropipéridine
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
WO2008062478A3 (en) Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
CO5261552A1 (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquino- linas 4-carboxiamino-2-sustituidas
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
NZ609761A (en) Monohydrate of an azaadamantane derivative
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
FR2938777B1 (fr) Catalyseur en coquille, procede de preparation et utilisation de ce catalyseur.
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
MX2009005249A (es) Compuestos organicos.
DE59207074D1 (de) 2-Substituierte Chinoline, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln

Legal Events

Date Code Title Description
FC Refusal